Abstract 584P
Background
CNS metastases are associated with high clinical burden and mortality risk in patients with advanced EGFR+ NSCLC. The phase III AENEAS study showed that aumolertinib, a novel third-generation EGFR-TKI, significantly improved median CNS PFS in comparison to gefitinib in treatment-naive EGFR+ NSCLC patients with CNS metastases (29.0 vs 8.3months, hazard ratios: 0.319). In this study, we explore whether aumolertinib could potentially delay or prevent symptomatic CNS metastases in EGFR+ NSCLC patients without baseline CNS metastasis.
Methods
We included all consecutive EGFR+ NSCLC patients who underwent first or second-line aumolertinib treatment without baseline CNS metastasis (April 2021 to February 2023). We estimated the cumulative incidence of subsequent symptomatic CNS metastases, CNS median PFS, and their associated risk factors using the Kaplan–Meier method and the log-rank test. Images obtained upon EGFR-TKI initiation and at the time of EGFR-TKI treatment failure. Follow-up brain scans were not mandatory, typically after the appearance of indicative symptoms. Supplementary follow-up telephone interviews were also employed.
Results
A total of 88 pts were enrolled. At data cutoff,the median follow-up was 21 months,with only 1 pt experienced symptomatic CNS metastases. The cumulative incidence of symptomatic CNS metastasis at 12, 18, and 24 months were 0%, 1.538%, and 1.538%, respectively.For the 62 pts who received second-line aumolertinib,the cumulative incidence of symptomatic CNS metastases at the same time points was 0%. However, the cumulative incidence curves of symptomatic CNS metastasis tended to reach a plateau after approximately 18 months.The cumulative incidence with aumolertinib was lower than historical data from first-generation EGFR-TKIs and also demonstrated a declining trend compared to historical data from the retrospective study of Osimertinib (1-2% at 12 months; 2-3% at 24 months; 11.8% at 36 months).
Conclusions
This is the first study to demonstrate that Aumolertinib can reduce the risk of symptomatic CNS metastasis in EGFR+ NSCLC patients without baseline CNS metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract